Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lisa Takagi

Managing Editor

Tokyo, Japan

Lisa provides editorial coverage of all aspects of Japan’s prescription drug market for Scrip and Pink Sheet, including company, market, pricing and regulatory developments, as well as publishing podcast content regularly in the local Japanese language.

Lisa brings close to a decade of experience working in either international teams or reporting, writing and editing, including in broadcast media through an internship as a TV reporter in Canada. Most recently, she covered the IT sector for ITmedia Enterprise in Japan. Lisa is bilingual in Japanese and English. She speaks basic French and Mandarin with keen interests in learning new languages. She holds an MA in Fine Art from Tokyo University of the Arts as well as a Master’s in Journalism from the University of King’s College in Halifax, Canada.

Latest From Lisa Takagi

Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics

Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.

Deal Watch Business Strategies

Takeda Eyes Further Filings For Dengue Vaccine But Timings Unclear

With Qdenga’s US approval process moving ahead with the granting of a Priority Review and the dengue vaccine's first market launch, in Indonesia, expected early next year, Takeda has recently referred to plans to expand the product into other countries as well. But precise timings as yet remain unclear. 

Vaccines Infectious Diseases

Kyowa Kirin To Offload Selected Mature Portfolio To Grünenthal

The Japanese and German firms agree to establish a joint company to handle 13 mature brands from Kyowa Kirin's portfolio, mainly focused on pain management and including Abstral and PecFent. Grünenthal will own 51% and plans to fully buy out the operation in early 2026.

Commercial Deals

Third Time Lucky As Japan Finally Approves Shionogi’s Oral COVID Antiviral

Shionogi’s once-daily oral COVID-19 antiviral finally gets Japan approval after being considered for the third time by an expert panel, paving the way for public availability of the country’s first such home-grown option in early December.

Japan Commercial

Astellas's First-In-Class CLDN18 Antibody Meets Phase III Gastric Endpoints

Novel candidate acquired from Ganymed in 2016 moves closer to first approval filing anywhere for a CLDN18-targeting antibody, and as a potential competitor for Opdivo in HER2-negative gastric cancer, following positive top-line Phase III results in the first-line combo setting. Results from GLOW trial in combination with CAPOX also awaited.

Cancer Clinical Trials

Researcher At Heart: Toichi Takenaka's Journey From 'Empty Lab' To CEO

Dr Toichi Takenaka, the first winner of the Lifetime Achievement Award in the inaugural Pharma Intelligence Awards Japan earlier this year, talks to Scrip about his journey from researcher to CEO and today as a mentor for Japanese bioventures. Starting his career in an “empty lab” in the 1960s motivated him to pursue a string of collaborations with universities in Japan and on to the discovery of four successful drugs.

Japan Business Strategies
See All
UsernamePublicRestriction

Register